A Phase 4 interventional study of celecoxib and Oxycodone in Osteoarthritis, sponsored by Pfizer. Terminated at 2 sites in United States. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-04-14.
Sponsored by Pfizer · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.
Among the 14 studies testing celecoxib in Osteoarthritis, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 10 in phase 4, and was the 9th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 41+
By country, each count listing its studies:
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 150 across the 14 interventional studies. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
39 studies in Osteoarthritis by Pfizer: 2 open now, 2 under way, 2 of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 39 studies in Osteoarthritis by Pfizer, this one is the 32nd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2008, is the only one in phase 4, and was the 12th registered.
Pfizer’s Osteoarthritis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing celecoxib in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 39 in Osteoarthritis:
This tab as a report to print or save as PDF → With an account.
The Purpose of this trial is to evaluate the use of a cross-over trial design in an osteoarthritis population. We will determine the inter- and intra-subject variability in osteoarthritis (OA) endpoints and evaluate if efficacy can be detected by measuring OA endpoints following treatment with 2 different types of analgesics in a crossover study of this design.
Methodology study to evaluate the use of a cross over design and gait analysis. The study was terminated by mutual consent with the study site at a meeting on the 1 April 2009, because of slow recruitment due to a high screen fail rate. The study was not stopped for safety reasons.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: celecoxib
Drug: Oxycodone
Drug: placebo
Change From Baseline in Knee Pain Intensity Measured by Numeric Rating Scale (NRS) at Week 12
The severity of arthritis pain in participant's signal knee at the time of the visit was assessed using an 11-point NRS, ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain.
Time frame: Baseline, Week 12
Change From Baseline in Knee Pain Intensity Measured by Visual Analog Scale (VAS) at Week 12
The severity of arthritis pain in participant's signal knee was assessed using a 100-millimeter (mm) VAS ranging from 0 mm = no pain and 100 mm = most severe pain. Higher score indicate more pain.
Time frame: Baseline, Week 12
Change From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Pain Subscale Score at Week 12
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). The index consists of 24 questions (5 pain, 2 stiffness, and 17 physical function). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. The WOMAC pain subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse pain. Pain subscale total score ranges from 0 to 20, with higher scores indicating worse pain.
Time frame: Baseline, Week 12
Change From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Physical Function Subscale Score at Week 12
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in in the study joint during past 48 hours. The WOMAC physical function subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse physical function. Physical function subscale scores range from 0 to 68, where higher scores indicated more difficulty in performing daily activities.
Time frame: Baseline, Week 12
Change From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Stiffness Subscale Score at Week 12
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). Stiffness was defined as a sensation of decreased ease of movement in study joint. The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the in the study joint during the past 48 hours. The WOMAC stiffness subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse stiffness. The stiffness subscale score ranges from 0 to 8, where higher scores indicated worse stiffness.
Time frame: Baseline, Week 12
Change From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Total Score at Week 12
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). The WOMAC composite index was the sum of 24 individual questions regarding subscales of pain, stiffness and physical function (for each item score range: 0 \[minimum\] to 4 \[maximum\], higher score indicating worse study joint condition). Total score was sum of the 3 subscale scores, giving a possible overall score range of 0 (minimum) to 96 (maximum). Higher score indicating the worse level of pain, stiffness and physical function.
Time frame: Baseline, Week 12
Change From Baseline in Knee Adduction Moment at Week 12
Adduction (external) moment was defined as the ground-generated torque that forces the distal tibia toward the midline of the body, which forces the knee away from the midline, into a varus or "bow-legged" position. External knee adduction moment was assessed as percent body weight\*height (%BW\*ht).
Time frame: Baseline, Week 12
Change From Baseline in Quadriceps Inhibition at Week 12
Quadriceps inhibition was assessed in terms of flexion-extension range of motion and normalized mid stance knee flexion angle in degrees.
Time frame: Baseline, Week 12
Change From Baseline in Peak Ground Reaction Force at Week 12
Change from baseline in peak ground reaction force in body weight\*seconds (BW\*sec) was assessed with the help of a multicomponent force plate.
Time frame: Baseline, Week 12
Change From Baseline in Total Ground Reaction Force at Week 12
Change from baseline in total ground reaction force in body weight\*seconds was assessed with the help of a multicomponent force plate.
Time frame: Baseline, Week 12
Change From Baseline in Stride Length at Week 12
The level walking was assessed by stride length; assessment was done based on 6 stride cycles over a range of walking speeds.
Time frame: Baseline, Week 12
Change From Baseline in Walking Speed at Week 12
Change from baseline in walking speed in meters per second was assessed.
Time frame: Baseline, Week 12
Change From Baseline in Cadence at Week 12
Cadence was defined as the rate at which a person walk, expressed in steps per minute.
Time frame: Baseline, Week 12
Change From Baseline in Patient Global Assessment of Arthritic Condition (PGAAC) Score at Week 12
The PGAAC is self-administered measure in which participants answered the following question: "considering all the ways the OA in your signal knee affects you, how are you doing today?". Participants rated their condition using the following scale: 1= very good (no symptoms and no limitation of normal activities); 2= good (mild symptoms and no limitation of normal activities); 3= fair (moderate symptoms and limitation of some normal activities); 4= poor (severe symptoms and inability to carry out most normal activities); 5= very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.
Time frame: Baseline, Week 12
| Milestone | Placebo Then Celecoxib Then Oxycodone | Placebo Then Oxycodone Then Celecoxib | Celecoxib Then Placebo Then Oxycodone | Celecoxib Then Oxycodone Then Placebo | Oxycodone Then Placebo Then Celecoxib | Oxycodone Then Celecoxib Then Placebo |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Then Celecoxib Then Oxycodone | Placebo Then Oxycodone Then Celecoxib | Celecoxib Then Placebo Then Oxycodone | Celecoxib Then Oxycodone Then Placebo | Oxycodone Then Placebo Then Celecoxib | Oxycodone Then Celecoxib Then Placebo |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Then Celecoxib Then Oxycodone | Placebo Then Oxycodone Then Celecoxib | Celecoxib Then Placebo Then Oxycodone | Celecoxib Then Oxycodone Then Placebo | Oxycodone Then Placebo Then Celecoxib | Oxycodone Then Celecoxib Then Placebo |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Then Celecoxib Then Oxycodone | Placebo Then Oxycodone Then Celecoxib | Celecoxib Then Placebo Then Oxycodone | Celecoxib Then Oxycodone Then Placebo | Oxycodone Then Placebo Then Celecoxib | Oxycodone Then Celecoxib Then Placebo |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Then Celecoxib Then Oxycodone | Placebo Then Oxycodone Then Celecoxib | Celecoxib Then Placebo Then Oxycodone | Celecoxib Then Oxycodone Then Placebo | Oxycodone Then Placebo Then Celecoxib | Oxycodone Then Celecoxib Then Placebo |
|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
The severity of arthritis pain in participant's signal knee at the time of the visit was assessed using an 11-point NRS, ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain.
No measurements were reported for this outcome.
The severity of arthritis pain in participant's signal knee was assessed using a 100-millimeter (mm) VAS ranging from 0 mm = no pain and 100 mm = most severe pain. Higher score indicate more pain.
No measurements were reported for this outcome.
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). The index consists of 24 questions (5 pain, 2 stiffness, and 17 physical function). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. The WOMAC pain subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse pain. Pain subscale total score ranges from 0 to 20, with higher scores indicating worse pain.
No measurements were reported for this outcome.
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in in the study joint during past 48 hours. The WOMAC physical function subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse physical function. Physical function subscale scores range from 0 to 68, where higher scores indicated more difficulty in performing daily activities.
No measurements were reported for this outcome.
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). Stiffness was defined as a sensation of decreased ease of movement in study joint. The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the in the study joint during the past 48 hours. The WOMAC stiffness subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse stiffness. The stiffness subscale score ranges from 0 to 8, where higher scores indicated worse stiffness.
No measurements were reported for this outcome.
WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). The WOMAC composite index was the sum of 24 individual questions regarding subscales of pain, stiffness and physical function (for each item score range: 0 \[minimum\] to 4 \[maximum\], higher score indicating worse study joint condition). Total score was sum of the 3 subscale scores, giving a possible overall score range of 0 (minimum) to 96 (maximum). Higher score indicating the worse level of pain, stiffness and physical function.
No measurements were reported for this outcome.
Adduction (external) moment was defined as the ground-generated torque that forces the distal tibia toward the midline of the body, which forces the knee away from the midline, into a varus or "bow-legged" position. External knee adduction moment was assessed as percent body weight\*height (%BW\*ht).
No measurements were reported for this outcome.
Quadriceps inhibition was assessed in terms of flexion-extension range of motion and normalized mid stance knee flexion angle in degrees.
No measurements were reported for this outcome.
Change from baseline in peak ground reaction force in body weight\*seconds (BW\*sec) was assessed with the help of a multicomponent force plate.
No measurements were reported for this outcome.
Change from baseline in total ground reaction force in body weight\*seconds was assessed with the help of a multicomponent force plate.
No measurements were reported for this outcome.
The level walking was assessed by stride length; assessment was done based on 6 stride cycles over a range of walking speeds.
No measurements were reported for this outcome.
Change from baseline in walking speed in meters per second was assessed.
No measurements were reported for this outcome.
Cadence was defined as the rate at which a person walk, expressed in steps per minute.
No measurements were reported for this outcome.
The PGAAC is self-administered measure in which participants answered the following question: "considering all the ways the OA in your signal knee affects you, how are you doing today?". Participants rated their condition using the following scale: 1= very good (no symptoms and no limitation of normal activities); 2= good (mild symptoms and no limitation of normal activities); 3= fair (moderate symptoms and limitation of some normal activities); 4= poor (severe symptoms and inability to carry out most normal activities); 5= very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.
No measurements were reported for this outcome.
Collected over From signing of informed consent to 28 days after the last study drug administration (up to 17 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/6 (0%) | 5/6 (83.3%) |
| Celecoxib 100 mg | — | 0/6 (0%) | 4/6 (66.7%) |
| Oxycodone 20 mg | — | 0/6 (0%) | 6/6 (100%) |
| Event | Placebo | Celecoxib 100 mg | Oxycodone 20 mg |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 3/6 |
| NauseaGastrointestinal disorders | 1/6 | 2/6 | 3/6 |
| SomnolenceNervous system disorders | 1/6 | 0/6 | 3/6 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/6 | 2/6 |
| HeadacheNervous system disorders | 0/6 | 1/6 | 2/6 |
| Vision blurredEye disorders | 1/6 | 0/6 | 0/6 |
| DyspepsiaGastrointestinal disorders | 0/6 | 1/6 | 1/6 |
| FlatulenceGastrointestinal disorders | 0/6 | 1/6 | 1/6 |
| ChillsGeneral disorders | 0/6 | 0/6 | 1/6 |
| DizzinessNervous system disorders | 1/6 | 1/6 | 1/6 |
Baseline analysis population included all randomized participants who received at least 1 dose of study medication.
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 62.5 ± 4.8 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 2 |
| Male | 4 |
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jan 2008 to primary completion in Jun 2009, 16 months.
Results were first posted in Apr 2021, 11 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Celecoxib · Oxycodone